Valneva SE (VALN) AI Stock Analysis

Valneva SE is a specialized vaccine company dedicated to advancing prophylactic vaccines for infectious diseases with significant unmet medical needs. Founded in 1998 and based in Saint-Herblain, France, the company commercializes IXIARO, an inactivated Japanese encephalitis vaccine for travelers, and DUKORAL, an oral vaccine targeting cholera and heat-labile toxin producing E. coli. It also developed the COVID-19 vaccine candidate VLA2001 and is advancing VLA1553 in Phase III trials for chikungunya virus infection. Additionally, Valneva partners with Pfizer, Inc. to co-develop the Lyme disease vaccine candidate VLA15, and collaborates with Instituto Butantan for single-shot chikungunya vaccine development.

Valneva's annual revenue rose from $153.7M in FY2023 to $169.6M in FY2024 and reached $174.7M in FY2025, reflecting 3.0% growth that year. Gross margin stood at 38.7% in FY2025, while operating margin fell to -46.7% and net income totaled -$115.2M, compared to net income of -$12.2M in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue growth declined 27.7% year-over-year, and trailing twelve-month revenue reached $142.9M with a profit margin of -110.3%. The company's five-year revenue CAGR from FY2020 to FY2025 is 9.6%.

As of June 30, 2026, Valneva held $121.5M in cash and short-term investments against total debt of $210.1M, resulting in net debt of $88.7M. Shareholders' equity was $81.1M, supporting a debt-to-equity ratio of 2.59 and a current ratio of 2.16. In FY2025, operating cash flow was -$52.9M, free cash flow was -$57.4M, and capital expenditures were $4.5M. The company's share count has increased 88.0% over the past five years.

At $5.61 per share, Valneva trades at an enterprise value of $706.4M and a market capitalization of $532.0M. Its forward price-to-earnings multiple is 3.6x, compared to the median of 17.3x for its US-listed Healthcare peers. Its enterprise value-to-EBITDA ratio is 26.9x, above the peer median of 12.0x, while its price-to-sales ratio is 3.7x compared to the peer median of 4.1x. Over the past year, VALN dropped 45.2%, trailing the S&P 500 return of 16.8%, and is down 80.0% over five years.

Valneva holds 3 Strong Buy ratings and 1 Strong Sell rating among analysts. The mean price target of $12.25 represents an upside of 118.4% relative to the last close of $5.61. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$1.13 and revenue of $151.0M. For the next fiscal year, consensus models call for EPS of $1.19 on revenue of $283.4M, representing 87.6% revenue growth. Valneva beat EPS estimates in 0 of the last 4 quarters, with next earnings scheduled for November 19, 2026.

This page is an AI-written research summary of Valneva SE (VALN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VALN income statement, VALN balance sheet, VALN key metrics, VALN analyst forecast, VALN chart. See the VALN stock overview for the latest quote and news.